Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
about
Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitorsTrial WatchFunctional Significance of CD57 Expression on Human NK Cells and Relevance to DiseaseMicroenvironmental Targets in SarcomaGranzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Oncogene withdrawal engages the immune system to induce sustained cancer regression.Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.Recognition of tumors by the innate immune system and natural killer cells.TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.Daily intake of probiotics with high IFN-γ/IL-10 ratio increases the cytotoxicity of human natural killer cells: a personalized probiotic approach.Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differentiaImatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.PDL1 expression is an independent prognostic factor in localized GIST.Targeted therapy in Ewing sarcoma.Exploiting antitumor immunity to overcome relapse and improve remission duration.Increased NK Cell Maturation in Patients with Acute Myeloid LeukemiaInhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.The synergistic interaction between the calcineurin B subunit and IFN-γ enhances macrophage antitumor activity.Trial watch: Prognostic and predictive value of the immune infiltrate in cancerNatural killer cells in non-hematopoietic malignanciesPhase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinibNoncanonical roles of the immune system in eliciting oncogene addictionBlood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor.Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors.Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Natural Killer Cell Diversity in Viral Infection: Why and How Much?Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer.KIT oncogene inhibition drives intratumoral macrophage M2 polarization.Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Immune parameters affecting the efficacy of chemotherapeutic regimens.Combining immunotherapy and targeted therapies in cancer treatment.
P2860
Q24306212-0067A731-7A60-4637-8506-42D69106D4BBQ24618653-D992D020-2E8F-4727-86E4-18297C601DAEQ27022458-621F090E-D150-45DB-9868-72657E8E2C90Q28081400-07CE1770-5ECD-4C15-BF40-98307BFA4C25Q30554443-9AB325AF-4655-4C73-B010-D0F5BAB9BD06Q33807742-1EAB983C-3382-47FF-84D8-D305BA9CB164Q33987633-ABE308D7-7F74-43A9-81EC-BBFD07AA3ADEQ34028872-AC7A3E84-A7D9-4279-A6D3-39AFC79E6892Q34083140-9EB1E8AB-D997-43C6-830C-1E8778F3D32FQ34361976-B5A2BACC-2C23-4995-845A-3A62A8E6C71CQ34441128-017E5255-2330-472B-93A6-E0A10A52796DQ34496462-755B5D06-F48E-4E40-993B-78174E505D23Q34541424-B61C44DA-2553-4884-BC48-18E00E6BA923Q35156027-D368108E-1969-4306-BBE5-8EF8DAB48AC7Q35743162-121F830A-46F9-415F-B769-4CFED08C624FQ35753251-5352E26C-2EC6-4189-A1CA-BFEEB2A49920Q35798839-9014A69B-4355-48F3-B5AB-76AF96E353CBQ36011879-83DB91FD-F76F-4B87-996B-F992C850276DQ36044604-41DFFDAE-4D8A-48DF-AD9E-C2DB7E4CDEF4Q36256263-33C5D425-DCE9-4CC1-B857-F107C0D56677Q36261782-724869B8-F11B-45CB-B5FF-91DB4387711BQ36346996-DC756663-A541-4AAB-8D7B-7E62B89C9CC1Q36456483-7D60AFF9-3DF9-4B31-B00B-0D0C60D56C5FQ36486204-24CB9186-8ECA-4ABC-AABB-C6B3C7EEC34FQ36694926-E8DC433B-99EC-4D9B-AFA1-E9ABDF58F1E3Q36694931-A7CD428F-8CFB-4E74-ABAB-30285117DC7CQ36821572-30D6878C-7568-4463-A440-1D506BB50462Q36866959-96EA1006-BE4B-4914-8F72-643BB004CF8FQ36931816-76736397-79AA-4E5D-A20B-61EDA3359AAAQ36979386-869DC721-17C3-48AB-92C7-684B48150DF0Q37206680-25B54277-CD4C-4216-8435-A8B7D46E9558Q37222064-7A58C583-EA85-42A2-9C6F-1AC617C1D9C6Q37252674-C9F59EF8-D7EC-4E51-9F40-F5138BC0C303Q37286646-807A99A5-B738-490D-B9A0-CEB10046361EQ37392676-A132EA87-2B39-4A96-855D-E7CE11EDC099Q37397817-A58B145C-C655-4A21-9D9E-D775492731A5Q37439660-020C865F-1C8A-4AD3-B6FC-F6359D3D6A83Q37616478-5E069597-0F71-49D4-95F1-3EE897F28270Q37848665-AA6DF34F-EB58-4FA1-98D6-3418753DE387Q37995939-82229325-8E98-4BD8-BBA2-87F8536AAB8C
P2860
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@en
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@nl
type
label
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@en
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@nl
prefLabel
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@en
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@nl
P2093
P50
P1433
P1476
Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.
@en
P2093
Caroline Flament
Christophe Borg
Cédric Ménard
Céline Nonn
François Ghiringhelli
Jean-François Emile
Julien Taïeb
Nicolas F Delahaye
P304
P356
10.1158/0008-5472.CAN-08-3807
P407
P50
P577
2009-04-07T00:00:00Z